Recombinant OLIG2 antibody (AA 200-300)
Quick Overview for Recombinant OLIG2 antibody (AA 200-300) (ABIN7871942)
Target
See all OLIG2 AntibodiesAntibody Type
Reactivity
Host
Clonality
Conjugate
Application
Grade
Clone
-
-
Binding Specificity
- AA 200-300
-
Purpose
- OLIG2 Antibody (azide and preservative free)
-
Purification
- Protein A/G affinity
-
Immunogen
- A recombinant partial protein sequence (within amino acids 200-300) from the human protein was used as the immunogen for the OLIG2 antibody.
-
Isotype
- IgG, kappa
-
-
-
-
Application Notes
- Optimal dilution of the OLIG2 antibody should be determined by the researcher.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 1 mg/mL
-
Buffer
- 1 mg/mL in 1X PBS, BSA free, sodium azide free
-
Preservative
- Azide free
-
Storage
- -20 °C
-
Storage Comment
- Aliquot the OLIG2 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.
-
-
- OLIG2 (Oligodendrocyte Lineage Transcription Factor 2 (OLIG2))
-
Alternative Name
- OLIG2
-
Background
- Olig2, a basic helix-loop-helix transcription factor, is involved in oligo-dendroglial specification. Olig2 expression has been reported in most glial tumors, such as oligodendrogliomas and astrocytomas. Although more than half of glioblastomas are positive for Olig2, expression is very weak in terms of both percentage of labeled cells and intensity. No Olig2 expression has been found in the non-glial tumors including neuroepithelial tumors, ependymomas, sub-ependymomas, medulloblastomas, and non-neuroepithelial tumors, such as CNS lymphomas, meningiomas, schwannomas, atypical teratoid/rhabdoid tumor, and haemangioblastomas. Compared to the strong staining seen in glioma samples, a weak expression is observed in non-tumoral brain tissue.
-
UniProt
- Q13516
Target
-